Ben Salah H, Bahri M, Dhouib F, Daoud J
Service de radiothérapie, CHU Habib-Bourguiba, rue Majida-Boulila, 3029 Sfax, Tunisie; Faculté de médecine, université de Sfax, rue Majida-Boulila, 3029 Sfax, Tunisie.
Service de radiothérapie, CHU Habib-Bourguiba, rue Majida-Boulila, 3029 Sfax, Tunisie; Faculté de médecine, université de Sfax, rue Majida-Boulila, 3029 Sfax, Tunisie.
Cancer Radiother. 2016 Dec;20(8):830-832. doi: 10.1016/j.canrad.2016.07.100. Epub 2016 Oct 25.
The available data in the literature show that for gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, postoperative chemoradiotherapy improves disease-free survival after surgery with D0 or D1 lymph node dissection (and perhaps D2) as well as in case of positive node or R1 resection. With the publications of perioperative chemotherapy trials, the role of postoperative radiotherapy in the therapeutic arsenal of gastric adenocarcinoma or gastroesophageal junction adenocarcinoma becomes difficult to define. Postoperative radiotherapy is indicated in case of R1 resection.
文献中的现有数据表明,对于胃腺癌或胃食管交界腺癌,术后放化疗可改善行D0或D1淋巴结清扫(可能还有D2)术后以及淋巴结阳性或R1切除患者的无病生存期。随着围手术期化疗试验的发表,术后放疗在胃腺癌或胃食管交界腺癌治疗手段中的作用变得难以界定。R1切除的情况下需进行术后放疗。